- |||||||||| TmMSTN-01 / Gilead
Trial completion, Trial completion date, Trial primary completion date, CAR T-Cell Therapy: CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov) - Aug 2, 2024
P1, N=54, Completed,
Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Nov 2023
- |||||||||| CART-PSMA- TGF?RDN cells / Gilead
Enrollment closed, Metastases: UPCC 32816: CART-PSMA-TGF?RDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Apr 25, 2024
P1, N=23, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Nov 2023 Recruiting --> Active, not recruiting
- |||||||||| TmPSMA-02 / Gilead
Enrollment open, Metastases: TmPSMA-02 in mCRPC (clinicaltrials.gov) - Feb 6, 2024
P1, N=18, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| TmMSTN-01 / Gilead
Enrollment closed, Enrollment change, CAR T-Cell Therapy: CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov) - Nov 2, 2023
P1, N=65, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=27 --> 65
- |||||||||| TmPSMA-02 / Gilead
New P1 trial, Metastases: TmPSMA-02 in mCRPC (clinicaltrials.gov) - Sep 21, 2023
P1, N=18, Not yet recruiting,
- |||||||||| NY-ESO-1 TCR-T cell therapy / Gilead
Phase I TCR Trial Experience Targeting HPV-16-Driven Tumors () - Jun 15, 2023 - Abstract #IOSUMMITEUROPE2023IO_SUMMIT_EUROPE_157;
However, durable responses are still elusive. Recent translational data point to various mechanisms of treatment resistance employed by the tumor in context of TCR-engineered T cell therapy.
- |||||||||| TmGPC2 01 CAR-T / Gilead
Enrollment open, Trial initiation date, CAR T-Cell Therapy: 22CT012: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - May 24, 2023
P1, N=30, Recruiting,
Recent translational data point to various mechanisms of treatment resistance employed by the tumor in context of TCR-engineered T cell therapy. Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> May 2023
- |||||||||| Tn MUC1 CAR T-cell therapy / Gilead
Enrollment change, Trial completion date, Trial termination, CAR T-Cell Therapy, Metastases: CART-TnMUC1-01: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (clinicaltrials.gov) - Apr 19, 2023
P1, N=16, Terminated,
Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> May 2023 N=112 --> 16 | Trial completion date: Oct 2036 --> Dec 2022 | Active, not recruiting --> Terminated; The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.
- |||||||||| Kineret (anakinra) / SOBI
Enrollment change, Trial completion date, Trial termination, CAR T-Cell Therapy, Metastases: A Study of CART-PSMA-TGF?RDN in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Apr 13, 2023
P1, N=16, Terminated,
N=112 --> 16 | Trial completion date: Oct 2036 --> Dec 2022 | Active, not recruiting --> Terminated; The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. N=50 --> 16 | Trial completion date: Nov 2036 --> Nov 2022 | Active, not recruiting --> Terminated; Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.
- |||||||||| TmGPC2 01 CAR-T / Gilead
Trial initiation date, CAR T-Cell Therapy: 22CT012: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Mar 20, 2023
P1, N=30, Not yet recruiting,
N=50 --> 16 | Trial completion date: Nov 2036 --> Nov 2022 | Active, not recruiting --> Terminated; Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study. Initiation date: Apr 2023 --> Oct 2023
- |||||||||| CART-PSMA- TGFβRDN cells / Tmunity Therap, TmPSMA-02 / Tmunity Therap
Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_672;
P1
Background We previously reported preliminary safety and efficacy results from a multi-center Phase 1 trial of CART-PSMA-TGFβRDN T-cells (TmPSMA-01; NCT04227275 ) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)...Knowledge gained from these studies supported the development of a next-generation PSMA-targeting CAR, TmPSMA-02, to improve safety while maintaining anti-tumor activity and will be explored in a multi-center, Ph1/2 trial for pts with mCRPC...The clinical study protocol and the informed consent form (ICF) were both reviewed and approved by the properly chartered IRBs and Independent Ethics Committee before the study commenced. Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study.
- |||||||||| Trial initiation date: CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM (clinicaltrials.gov) - Sep 23, 2022
P1, N=18, Not yet recruiting,
Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study. Initiation date: Jun 2022 --> Mar 2023
- |||||||||| CART-PSMA- TGF?RDN cells / Gilead
Enrollment open, Trial completion date, Trial primary completion date, Metastases: UPCC 32816: CART-PSMA-TGF?RDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Mar 21, 2022
P1, N=19, Recruiting,
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2038 | Trial primary completion date: Sep 2022 --> Sep 2038
- |||||||||| Trial initiation date: CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM (clinicaltrials.gov) - Jan 11, 2022
P1, N=18, Not yet recruiting,
Active, not recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2038 | Trial primary completion date: Sep 2022 --> Sep 2038 Initiation date: Dec 2021 --> Jun 2022
- |||||||||| Kineret (anakinra) / SOBI, CART-PSMA- TGFβRDN cells / Tmunity Therap
Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC. (In-Person & On Demand | Level 1, West Hall - E7) - Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_326;
P1
The exact mechanisms driving the severe immune-mediated toxicities in this study are currently unclear. While this study has been closed to further enrollment, ongoing research efforts are aimed at exploring patient specific factors, tumor microenvironment factors, and the PSMA-CART construct (including both functional components and armored modules) to design future constructs of PSMA-CART that will enhance the efficacy/safety profile and allow for continued study of this novel therapy in the clinic.
- |||||||||| CART-PSMA- TGF?RDN cells / Gilead
Trial completion date, Trial primary completion date, Metastases: UPCC 32816: CART-PSMA-TGF?RDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 14, 2021
P1, N=18, Active, not recruiting,
While this study has been closed to further enrollment, ongoing research efforts are aimed at exploring patient specific factors, tumor microenvironment factors, and the PSMA-CART construct (including both functional components and armored modules) to design future constructs of PSMA-CART that will enhance the efficacy/safety profile and allow for continued study of this novel therapy in the clinic. Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- |||||||||| TmMSTN-01 / Gilead
Enrollment change, CAR T-Cell Therapy: CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov) - Jul 2, 2021
P1, N=27, Recruiting,
These results suggest that the antigen-loaded CHP nanogel can promote the local antigen-presentation to T-cells and represent a promising approach for improving the efficacy of adoptive T-cell therapy for gliomas. N=18 --> 27
- |||||||||| TmMSTN-01 / Gilead
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov) - Apr 22, 2021
P1, N=18, Recruiting,
Modified immune toxicity management could lead to identification of a manageable safety profile and therapeutically active dose. Trial completion date: Mar 2021 --> Mar 2025 | Trial primary completion date: Mar 2021 --> Mar 2025
- |||||||||| TmMSTN-01 / Gilead
Enrollment open, CAR T-Cell Therapy: CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov) - Jun 1, 2020
P1, N=18, Recruiting,
Active, not recruiting --> Recruiting | N=80 --> 112 | Trial completion date: Jul 2034 --> Oct 2036 Active, not recruiting --> Recruiting
- |||||||||| Kineret (anakinra) / SOBI
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Metastases: A Study of CART-PSMA-TGF?RDN in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - May 26, 2020
P1, N=50, Recruiting,
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting | N=18 --> 50 | Trial completion date: Apr 2022 --> Nov 2036 | Trial primary completion date: Nov 2020 --> Nov 2022
- |||||||||| NY-ESO-1 TCR-T cell therapy / Gilead
Trial completion date, Trial termination, Trial primary completion date, PD(L)-1 Biomarker: NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (clinicaltrials.gov) - May 7, 2020
P1, N=3, Terminated,
Active, not recruiting --> Recruiting | N=18 --> 50 | Trial completion date: Apr 2022 --> Nov 2036 | Trial primary completion date: Nov 2020 --> Nov 2022 Trial completion date: Jan 2033 --> Feb 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2033 --> Feb 2020; Sponsor has terminated trial to pursue other targets.
- |||||||||| TmMSTN-01 / Gilead
Enrollment closed, Enrollment change, CAR T-Cell Therapy: CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov) - Apr 24, 2020
P1, N=3, Active, not recruiting,
Trial completion date: Jan 2033 --> Feb 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2033 --> Feb 2020; Sponsor has terminated trial to pursue other targets. Recruiting --> Active, not recruiting | N=30 --> 3
- |||||||||| TmMSTN-01 / Gilead
Enrollment open, CAR T-Cell Therapy: CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov) - Feb 25, 2019
P1, N=30, Recruiting,
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
|
